심혈관질환(CVD) 역학 분석과 예측(2026-2035년)

CVD Epidemiology market is projected to register a strong CAGR during the forecast period (2026-2035).

Cardiovascular diseases remain the leading cause of mortality and disability worldwide, representing one of the most significant public health challenges across both developed and emerging economies. Major cardiovascular conditions include coronary artery disease, stroke, heart failure, peripheral artery disease, atrial fibrillation, rheumatic heart disease, cardiomyopathies, and hypertensive heart disease. According to recent Global Burden of Disease analyses, cardiovascular diseases continue to account for the largest share of global mortality, with disease burden increasing due to population growth, aging populations, and persistent exposure to modifiable risk factors.

Epidemiology analysis plays a critical role in understanding disease prevalence, incidence, mortality, risk factor distribution, patient demographics, healthcare utilization, and future disease forecasts. Governments, healthcare providers, pharmaceutical companies, research organizations, and public health agencies increasingly rely on epidemiological intelligence to support policy development, healthcare resource allocation, therapeutic development, and preventive health initiatives.

Market Drivers

Rising Global Burden of Cardiovascular Diseases

One of the primary drivers of market growth is the continuing increase in cardiovascular disease burden worldwide. Recent studies indicate that cardiovascular diseases remain the leading cause of death globally, with disease burden increasing over recent decades despite advances in treatment and prevention. Population aging and demographic shifts are contributing significantly to this trend.

The growing number of patients affected by cardiovascular conditions is creating strong demand for comprehensive epidemiological analysis and long-term disease forecasting.

Increasing Prevalence of Modifiable Risk Factors

The rising prevalence of hypertension, obesity, diabetes, dyslipidemia, tobacco use, physical inactivity, and unhealthy dietary patterns continues to drive cardiovascular disease incidence globally. These modifiable risk factors are major contributors to disease burden and are increasingly becoming the focus of epidemiological research and public health interventions.

Healthcare organizations require detailed epidemiological insights to evaluate risk factor trends and develop effective prevention strategies.

Expansion of Healthcare Data Infrastructure

The growth of electronic health records, disease registries, insurance databases, biobanks, and population health surveillance systems is improving access to large-scale healthcare datasets. These resources enable more accurate epidemiological analyses and facilitate real-time monitoring of disease patterns.

The increasing availability of high-quality health data is supporting the development of advanced epidemiological models and predictive analytics tools.

Growing Focus on Preventive Healthcare

Healthcare systems worldwide are shifting toward prevention-focused models aimed at reducing disease burden and controlling healthcare costs. Epidemiological analysis provides essential evidence for identifying high-risk populations, evaluating intervention effectiveness, and optimizing prevention programs.

The increasing emphasis on population health management is accelerating investment in cardiovascular epidemiology research and analytics.

Market Restraints

Data Quality and Standardization Challenges

Variations in healthcare reporting systems, diagnostic criteria, coding practices, and data collection methodologies can create inconsistencies across epidemiological datasets.

These challenges may limit comparability between regions and affect the accuracy of disease burden assessments.

Underdiagnosis in Low-Resource Settings

Many low- and middle-income countries continue to face limitations in cardiovascular screening, diagnosis, and disease surveillance infrastructure.

Underdiagnosis and incomplete reporting can lead to underestimation of true disease prevalence and complicate epidemiological forecasting efforts.

Complex Disease Interactions

Cardiovascular diseases are influenced by multiple interacting factors including genetics, lifestyle behaviors, environmental exposures, socioeconomic conditions, and comorbidities.

The complexity of these relationships can create challenges in accurately quantifying risk factor contributions and predicting future disease trends.

Technology and Segment Insights

The global cardiovascular disease epidemiology analysis market can be segmented by disease type, risk factor category, demographic group, data source, application, end user, and geography.

By disease type, the market includes coronary artery disease, stroke, heart failure, peripheral artery disease, atrial fibrillation, hypertensive heart disease, rheumatic heart disease, cardiomyopathies, congenital heart disease, and other cardiovascular disorders. Coronary artery disease and stroke account for a significant share of disease burden and epidemiological research activity due to their high prevalence and mortality rates globally.

By risk factor category, the market includes hypertension, obesity, diabetes, hyperlipidemia, smoking, unhealthy diet, physical inactivity, chronic kidney disease, environmental exposures, and genetic predisposition. Hypertension remains one of the most significant contributors to global cardiovascular disease burden.

By demographic group, the market includes pediatric populations, adults, geriatric populations, gender-specific analyses, and region-specific assessments. Adult and elderly populations account for the largest share due to increasing disease incidence with advancing age.

By data source, the market includes electronic health records, national health surveys, disease registries, insurance claims databases, hospital records, mortality databases, and public health surveillance systems. Population-based registries and healthcare databases remain essential sources of epidemiological intelligence.

By application, the market includes prevalence analysis, incidence forecasting, mortality assessment, healthcare planning, risk stratification, prevention strategy development, policy evaluation, and clinical research support. Disease burden assessment and healthcare planning represent major application areas due to increasing healthcare resource demands.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, government agencies, public health organizations, contract research organizations, and healthcare consulting firms. Government agencies and public health organizations remain major users because of their responsibility for disease surveillance and population health planning.

Technological advancements are transforming epidemiological analysis through artificial intelligence, machine learning, predictive modeling, natural language processing, real-world evidence platforms, and population health analytics systems. These technologies enable more accurate disease forecasting, patient segmentation, and healthcare planning.

The integration of genomic data, wearable device information, lifestyle metrics, and electronic health records is creating more sophisticated epidemiological models capable of supporting precision prevention and personalized healthcare initiatives.

Geographically, North America dominates the market due to extensive healthcare databases, strong research infrastructure, and significant cardiovascular research investments. Europe maintains a substantial market presence supported by established public health systems and comprehensive disease registries. Asia-Pacific is expected to witness the fastest growth due to rising cardiovascular disease prevalence, large patient populations, increasing healthcare expenditure, and expanding epidemiological research capabilities. Latin America and the Middle East & Africa are gradually strengthening disease surveillance systems and cardiovascular health programs.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, academic institutions, public health agencies, contract research organizations, healthcare intelligence firms, and population health technology companies. Organizations are investing heavily in advanced analytics platforms, real-world evidence capabilities, predictive modeling technologies, and integrated healthcare intelligence solutions.

Strategic collaborations among healthcare providers, academic institutions, government agencies, and technology companies are becoming increasingly common as stakeholders seek to improve disease surveillance, forecasting accuracy, and healthcare planning capabilities.

The growing emphasis on value-based healthcare, preventive medicine, and population health management is expected to create significant opportunities for providers of cardiovascular epidemiology analysis and healthcare intelligence solutions.

Conclusion

The global cardiovascular disease epidemiology analysis market is poised for strong growth through 2031, supported by the increasing global burden of cardiovascular diseases, rising prevalence of major risk factors, expanding healthcare data infrastructure, and growing demand for evidence-based healthcare planning. Cardiovascular diseases remain the leading cause of mortality worldwide, creating an ongoing need for accurate epidemiological intelligence and disease forecasting capabilities. While challenges related to data quality, underreporting, and disease complexity remain, advances in artificial intelligence, real-world evidence generation, and population health analytics are expected to significantly enhance epidemiological research and support more effective cardiovascular disease prevention and management strategies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, patient populations, cardiovascular disease categories, and healthcare systems.
• Competitive Landscape: Understand emerging research initiatives, epidemiological methodologies, and strategic developments.
• Market Drivers and Future Trends: Assess major growth factors influencing disease surveillance and healthcare planning.
• Actionable Recommendations: Support policy development, healthcare resource allocation, prevention programs, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, public health agencies, academic institutions, healthcare providers, consultants, and investors.

What Businesses Use Our Reports For

Disease burden assessment, epidemiological forecasting, healthcare planning, cardiovascular prevention strategy development, clinical research support, market opportunity analysis, policy evaluation, healthcare investment decisions, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Global and regional prevalence, incidence, mortality, and patient population analysis
• Cardiovascular risk factor trends, disease burden assessment, and epidemiological forecasting
• Healthcare policy evaluation, prevention strategy assessment, and population health insights
• Competitive intelligence, research developments, and future market opportunity analysis.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Global Cardiovascular Disease Epidemiology Overview
  • 1.1.1 Global Disease Burden Snapshot
  • 1.1.2 Key Epidemiological Trends by Age
  • 1.1.3 Gender-Based Disease Distribution Trends
  • 1.1.4 Regional Incidence & Prevalence Highlights
  • 1.1.5 Diagnosed Population Forecast Summary
  • 1.1.6 Mortality Burden Forecast Summary
  • 1.1.7 Key Structural Epidemiology Shifts (2025-2045)
• 1.2 Key Findings & Strategic Insights
  • 1.2.1 High-Growth Patient Demographics
  • 1.2.2 High-Risk Cardiovascular Segments
  • 1.2.3 Emerging Regional Burden Hotspots
  • 1.2.4 Healthcare Access & Diagnosis Gap Insights
  • 1.2.5 Long-Term Population Risk Outlook

2. Cardiovascular Disease Epidemiology Overview

• 2.1 Definition & Classification of Cardiovascular Diseases
  • 2.1.1 Coronary Artery Disease
  • 2.1.2 Heart Failure
  • 2.1.3 Hypertension
  • 2.1.4 Stroke & Cerebrovascular Diseases
  • 2.1.5 Arrhythmias
  • 2.1.6 Peripheral Artery Disease
  • 2.1.7 Valvular Heart Disease
  • 2.1.8 Congenital Heart Disease
• 2.2 Pathophysiology & Disease Progression
  • 2.2.1 Atherosclerosis Development Mechanisms
  • 2.2.2 Endothelial Dysfunction
  • 2.2.3 Cardiac Remodeling & Fibrosis
  • 2.2.4 Metabolic Dysfunction & Cardiovascular Risk
  • 2.2.5 Inflammatory Mechanisms in CVD
• 2.3 Epidemiology Burden Framework
  • 2.3.1 Incidence Burden Analysis
  • 2.3.2 Prevalence Burden Analysis
  • 2.3.3 Diagnosed Population Assessment
  • 2.3.4 Mortality Burden Analysis
  • 2.3.5 Disability & Quality-of-Life Burden

3. Disease & Unmet Need Analysis

• 3.1 Global Epidemiology Burden by Disease Type
  • 3.1.1 Coronary Artery Disease Burden
  • 3.1.2 Heart Failure Burden
  • 3.1.3 Arrhythmia Burden
  • 3.1.4 Hypertension Burden
  • 3.1.5 Stroke Burden
  • 3.1.6 Peripheral Artery Disease Burden
• 3.2 Unmet Diagnostic & Treatment Needs
  • 3.2.1 Underdiagnosed Population Trends
  • 3.2.2 Delayed Diagnosis Burden
  • 3.2.3 Treatment Access Gaps
  • 3.2.4 Mortality Associated with Late Intervention
  • 3.2.5 Rural vs Urban Healthcare Access Gaps
• 3.3 Healthcare System Burden
  • 3.3.1 Hospitalization Burden
  • 3.3.2 Readmission Burden
  • 3.3.3 ICU Dependency Trends
  • 3.3.4 Long-Term Chronic Disease Burden
  • 3.3.5 Economic & Productivity Burden

4. Age-Based Epidemiology Analysis

• 4.1 Pediatric Population Epidemiology
  • 4.1.1 Congenital Heart Disease Incidence
  • 4.1.2 Pediatric Hypertension Trends
  • 4.1.3 Childhood Obesity-Linked Cardiovascular Risk
  • 4.1.4 Pediatric Mortality Trends
• 4.2 Adult Population Epidemiology
  • 4.2.1 Coronary Artery Disease Incidence in Adults
  • 4.2.2 Hypertension Prevalence in Adults
  • 4.2.3 Obesity & Diabetes-Driven Cardiovascular Burden
  • 4.2.4 Adult Mortality Trends
• 4.3 Geriatric Population Epidemiology
  • 4.3.1 Heart Failure Prevalence in Elderly Population
  • 4.3.2 Atrial Fibrillation Trends in Aging Population
  • 4.3.3 Structural Heart Disease Burden
  • 4.3.4 Mortality & Hospitalization Trends in Elderly Population
• 4.4 Super-Aged Population Analysis
  • 4.4.1 Cardiovascular Burden in Population Aged 80+
  • 4.4.2 Multi-Morbidity Impact Assessment
  • 4.4.3 Long-Term Care Dependency Trends
  • 4.4.4 Survival & Chronic Disease Management Trends

5. Gender-Based Epidemiology Analysis

• 5.1 Male Cardiovascular Disease Epidemiology
  • 5.1.1 Male Coronary Artery Disease Burden
  • 5.1.2 Hypertension Trends in Male Population
  • 5.1.3 Lifestyle Risk Factors in Men
  • 5.1.4 Male Mortality Trends
• 5.2 Female Cardiovascular Disease Epidemiology
  • 5.2.1 Female Cardiovascular Disease Burden
  • 5.2.2 Post-Menopausal Cardiovascular Risk
  • 5.2.3 Underdiagnosis Trends in Women
  • 5.2.4 Female Mortality & Survival Trends
• 5.3 Gender Disparity Assessment
  • 5.3.1 Diagnosis Rate Differences
  • 5.3.2 Treatment Accessibility Differences
  • 5.3.3 Clinical Outcome Differences
  • 5.3.4 Mortality Variation by Gender

6. Epidemiology by Disease Segment

• 6.1 Coronary Artery Disease Epidemiology
  • 6.1.1 Incidence Forecast (2025-2045)
  • 6.1.2 Prevalence Forecast
  • 6.1.3 Diagnosed Population Trends
  • 6.1.4 Mortality Trends
  • 6.1.5 Age-Based Disease Distribution
  • 6.1.6 Gender-Based Disease Distribution
• 6.2 Heart Failure Epidemiology
  • 6.2.1 HFrEF Epidemiology Trends
  • 6.2.2 HFpEF Epidemiology Trends
  • 6.2.3 Hospitalization Burden
  • 6.2.4 Readmission Trends
  • 6.2.5 Mortality Forecast
• 6.3 Arrhythmia Epidemiology
  • 6.3.1 Atrial Fibrillation Trends
  • 6.3.2 Ventricular Arrhythmia Trends
  • 6.3.3 Sudden Cardiac Arrest Burden
  • 6.3.4 Device Implantation Trends
• 6.4 Hypertension Epidemiology
  • 6.4.1 Diagnosed Hypertension Population
  • 6.4.2 Resistant Hypertension Burden
  • 6.4.3 Treatment-Control Gap Analysis
  • 6.4.4 Hypertension-Related Mortality Trends
• 6.5 Stroke & Cerebrovascular Disease Epidemiology
  • 6.5.1 Ischemic Stroke Incidence Trends
  • 6.5.2 Hemorrhagic Stroke Trends
  • 6.5.3 Recurrence Burden Analysis
  • 6.5.4 Disability Burden Trends

7. Diagnostic & Treatment Access Intelligence

• 7.1 Diagnostic Landscape
  • 7.1.1 Biomarker-Based Diagnosis Trends
  • 7.1.2 Imaging Technology Adoption
  • 7.1.3 AI-Based Cardiovascular Diagnostics
  • 7.1.4 Wearable Monitoring Adoption Trends
• 7.2 Screening & Detection Analysis
  • 7.2.1 Hypertension Screening Programs
  • 7.2.2 Cholesterol Screening Trends
  • 7.2.3 Preventive Cardiology Programs
  • 7.2.4 Community-Based Screening Models
• 7.3 Treatment Access Analysis
  • 7.3.1 Public Healthcare Access Trends
  • 7.3.2 Insurance Coverage Impact
  • 7.3.3 Urban vs Rural Treatment Accessibility
  • 7.3.4 Access to Advanced Cardiovascular Care

8. Mortality & Survival Analysis

• 8.1 Cardiovascular Mortality Trends
  • 8.1.1 Total Global Mortality Forecast
  • 8.1.2 Mortality by Disease Segment
  • 8.1.3 Premature Cardiovascular Mortality Trends
  • 8.1.4 Age-Specific Mortality Trends
  • 8.1.5 Gender-Specific Mortality Trends
• 8.2 Survival Trends & Long-Term Outcomes
  • 8.2.1 Post-Myocardial Infarction Survival Trends
  • 8.2.2 Heart Failure Survival Analysis
  • 8.2.3 Stroke Survival Trends
  • 8.2.4 Chronic Disease Progression Trends

9. Competitive Epidemiology Landscape

• 9.1 Comparative Disease Burden Benchmarking
  • 9.1.1 High-Burden vs Low-Burden Regions
  • 9.1.2 Developed vs Emerging Market Burden
  • 9.1.3 Diagnosis Efficiency Benchmarking
  • 9.1.4 Mortality-to-Prevalence Ratio Benchmarking
• 9.2 Healthcare System Benchmarking
  • 9.2.1 Preventive Care Infrastructure Assessment
  • 9.2.2 Screening Program Benchmarking
  • 9.2.3 Treatment Accessibility Benchmarking
  • 9.2.4 Chronic Disease Management Efficiency

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Incidence & Prevalence Trends
  • 10.1.2 Diagnosed Population Trends
  • 10.1.3 Mortality Burden
  • 10.1.4 Aging Population Impact
  • 10.1.5 Healthcare Infrastructure Assessment
• 10.2 Europe
  • 10.2.1 Cardiovascular Disease Burden Trends
  • 10.2.2 Mortality & Hospitalization Trends
  • 10.2.3 Preventive Cardiology Programs
  • 10.2.4 Healthcare Access Trends
  • 10.2.5 Aging Population Impact
• 10.3 Asia-Pacific
  • 10.3.1 Urbanization-Driven Disease Burden
  • 10.3.2 Hypertension & Diabetes Impact
  • 10.3.3 Mortality Forecast Trends
  • 10.3.4 Rural vs Urban Diagnosis Gap
  • 10.3.5 Healthcare Infrastructure Trends
• 10.4 Latin America
  • 10.4.1 Disease Burden Trends
  • 10.4.2 Mortality & Disability Trends
  • 10.4.3 Healthcare Accessibility Challenges
  • 10.4.4 Preventive Screening Adoption
• 10.5 Middle East & Africa
  • 10.5.1 Metabolic Syndrome Burden
  • 10.5.2 Healthcare Infrastructure Gaps
  • 10.5.3 Mortality Burden Trends
  • 10.5.4 Public Health Intervention Analysis

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Incidence & Prevalence Trends
  • 11.1.2 Obesity & Diabetes Impact
  • 11.1.3 Mortality Trends
  • 11.1.4 Preventive Cardiology Programs
  • 11.1.5 Healthcare Spending Burden
• 11.2 Canada
  • 11.2.1 Disease Burden Trends
  • 11.2.2 Aging Population Impact
  • 11.2.3 Mortality Trends
  • 11.2.4 Healthcare Access Assessment
• 11.3 Germany
  • 11.3.1 Heart Failure Burden
  • 11.3.2 Mortality Trends
  • 11.3.3 Aging Population Impact
  • 11.3.4 Healthcare Infrastructure Analysis
• 11.4 United Kingdom
  • 11.4.1 NHS Cardiovascular Burden
  • 11.4.2 Hypertension Trends
  • 11.4.3 Mortality Forecast
  • 11.4.4 Preventive Healthcare Programs
• 11.5 France
  • 11.5.1 Epidemiology Trends
  • 11.5.2 Lifestyle Risk Factor Analysis
  • 11.5.3 Mortality Trends
  • 11.5.4 Diagnosis & Treatment Access Trends
• 11.6 Italy
  • 11.6.1 Aging Population Burden
  • 11.6.2 Heart Failure Trends
  • 11.6.3 Mortality Trends
  • 11.6.4 Chronic Disease Management Trends
• 11.7 Spain
  • 11.7.1 Cardiovascular Burden Trends
  • 11.7.2 Lifestyle-Linked Risk Factors
  • 11.7.3 Mortality Analysis
  • 11.7.4 Preventive Cardiology Trends
• 11.8 China
  • 11.8.1 Urbanization-Driven Disease Burden
  • 11.8.2 Hypertension & Stroke Trends
  • 11.8.3 Mortality Forecast
  • 11.8.4 Rural vs Urban Access Gaps
• 11.9 Japan
  • 11.9.1 Super-Aged Population Burden
  • 11.9.2 Heart Failure Epidemiology
  • 11.9.3 Mortality Trends
  • 11.9.4 Long-Term Care Dependency
• 11.10 India
  • 11.10.1 Premature Cardiovascular Mortality
  • 11.10.2 Diabetes & Hypertension Burden
  • 11.10.3 Rural vs Urban Trends
  • 11.10.4 Treatment Accessibility Challenges
• 11.11 South Korea
  • 11.11.1 Aging Population Trends
  • 11.11.2 Lifestyle Risk Analysis
  • 11.11.3 Mortality Trends
  • 11.11.4 Preventive Healthcare Initiatives
• 11.12 Australia
  • 11.12.1 Disease Burden Trends
  • 11.12.2 Indigenous Population Cardiovascular Burden
  • 11.12.3 Mortality Trends
  • 11.12.4 Preventive Cardiology Programs
• 11.13 Brazil
  • 11.13.1 Hypertension Burden
  • 11.13.2 Mortality Trends
  • 11.13.3 Public Healthcare System Impact
  • 11.13.4 Access-to-Care Challenges
• 11.14 Mexico
  • 11.14.1 Obesity-Driven Cardiovascular Burden
  • 11.14.2 Diabetes-Associated Risk Trends
  • 11.14.3 Mortality Analysis
  • 11.14.4 Screening Program Trends
• 11.15 Saudi Arabia
  • 11.15.1 Metabolic Syndrome Burden
  • 11.15.2 Healthcare Modernization Impact
  • 11.15.3 Mortality Trends
  • 11.15.4 Preventive Healthcare Adoption
• 11.16 South Africa
  • 11.16.1 Dual Burden of Infectious & Cardiovascular Diseases
  • 11.16.2 Healthcare Access Gaps
  • 11.16.3 Mortality Forecast
  • 11.16.4 Public Health Intervention Trends

12. Healthcare Policy & Reimbursement Landscape

• 12.1 Public Health & Prevention Policies
  • 12.1.1 WHO Cardiovascular Prevention Frameworks
  • 12.1.2 National Hypertension Screening Policies
  • 12.1.3 Tobacco & Obesity Control Programs
  • 12.1.4 Community Prevention Strategies
• 12.2 Reimbursement Landscape
  • 12.2.1 Public Reimbursement Trends
  • 12.2.2 Private Insurance Coverage Trends
  • 12.2.3 Reimbursement for Preventive Screening
  • 12.2.4 Access-to-Care Impact Assessment

13. Future Outlook & Strategic Insights

• 13.1 Long-Term Epidemiology Forecast
  • 13.1.1 High-Growth Patient Populations
  • 13.1.2 Emerging Risk Factor Trends
  • 13.1.3 Aging Population Impact Forecast
  • 13.1.4 Long-Term Mortality Outlook
• 13.2 Future Healthcare Trends
  • 13.2.1 AI-Based Preventive Cardiology Expansion
  • 13.2.2 Remote Monitoring Adoption Growth
  • 13.2.3 Precision Cardiology Development
  • 13.2.4 Community-Based Screening Expansion
• 13.3 Strategic Insights for Stakeholders
  • 13.3.1 Opportunities for Pharmaceutical Companies
  • 13.3.2 Opportunities for Diagnostic Companies
  • 13.3.3 Opportunities for Healthcare Providers
  • 13.3.4 Opportunities for Policymakers & Payers

14. Methodology & Data Framework

• 14.1 Epidemiology Research Methodology
  • 14.1.1 Incidence-Based Forecast Modeling
  • 14.1.2 Prevalence-Based Forecast Modeling
  • 14.1.3 Mortality Forecast Methodology
  • 14.1.4 Diagnosed Population Modeling
• 14.2 Data Sources & Validation
  • 14.2.1 WHO Database
  • 14.2.2 IHME Global Burden of Disease Database
  • 14.2.3 CDC & National Health Databases
  • 14.2.4 Hospital & Claims Databases
  • 14.2.5 Peer-Reviewed Literature & Registries
• 14.3 Forecasting Assumptions & Limitations
  • 14.3.1 Population Growth Assumptions
  • 14.3.2 Aging Demographic Assumptions
  • 14.3.3 Underdiagnosis & Underreporting Limitations
  • 14.3.4 Regional Data Variability Constraints